DE69840637D1 - Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen - Google Patents

Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen

Info

Publication number
DE69840637D1
DE69840637D1 DE69840637T DE69840637T DE69840637D1 DE 69840637 D1 DE69840637 D1 DE 69840637D1 DE 69840637 T DE69840637 T DE 69840637T DE 69840637 T DE69840637 T DE 69840637T DE 69840637 D1 DE69840637 D1 DE 69840637D1
Authority
DE
Germany
Prior art keywords
compositions
vaccines
chemokins
increasing
efficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69840637T
Other languages
English (en)
Inventor
Robert C Gallo
Anthony L Devico
Alfredo Garzino-Demo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Biotechnology Institute UMBI
Original Assignee
University of Maryland Biotechnology Institute UMBI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Biotechnology Institute UMBI filed Critical University of Maryland Biotechnology Institute UMBI
Application granted granted Critical
Publication of DE69840637D1 publication Critical patent/DE69840637D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69840637T 1997-12-11 1998-12-11 Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen Expired - Fee Related DE69840637D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6928197P 1997-12-11 1997-12-11
PCT/US1998/026291 WO1999029728A1 (en) 1997-12-11 1998-12-11 Method and composition to enhance the efficacy of a vaccine using chemokines

Publications (1)

Publication Number Publication Date
DE69840637D1 true DE69840637D1 (de) 2009-04-16

Family

ID=22087917

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840637T Expired - Fee Related DE69840637D1 (de) 1997-12-11 1998-12-11 Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen

Country Status (6)

Country Link
EP (1) EP1037918B1 (de)
AT (1) ATE424217T1 (de)
AU (1) AU1815899A (de)
CA (1) CA2314006A1 (de)
DE (1) DE69840637D1 (de)
WO (1) WO1999029728A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1073749B1 (de) * 1998-04-22 2006-01-11 Chiron Corporation Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US7708983B2 (en) 1998-12-11 2010-05-04 Alfredo Garzino-Demo Directional induction of immune response by co-administration of antigens with chemokines
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
CA2406853C (en) * 2000-04-21 2012-06-26 Chemocentryx, Inc. Methods and compositions for eliciting an immune response
WO2001080887A2 (en) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Methods and chemokin compositions for inducing an immune response
WO2002085409A2 (en) * 2001-04-12 2002-10-31 Chemocentryx Methods and compositions for inducing an immune response to an antigen
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
WO2006124013A2 (en) 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
CN115975053A (zh) * 2022-12-07 2023-04-18 南开大学 靶向新型冠状病毒的疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
JPH10507646A (ja) * 1995-06-07 1998-07-28 アイコス コーポレイション マクロファージ由来ケモカインおよびケモカインアナログ

Also Published As

Publication number Publication date
EP1037918A1 (de) 2000-09-27
EP1037918B1 (de) 2009-03-04
EP1037918A4 (de) 2004-11-03
CA2314006A1 (en) 1999-06-17
WO1999029728A1 (en) 1999-06-17
AU1815899A (en) 1999-06-28
ATE424217T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
AR026994A1 (es) Nuevas construcciones de expresion en plantas.
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
DE60143901D1 (de) Antisense-modulation der clusterinexpression
FI963070A (fi) Klooripyrimidiinivälituotteita
DE69840637D1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
ATE233557T1 (de) Verwendung von konjugiertes linolensäure zur steigerung der aktivität von natural killer- lymphozyten
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DE68911132D1 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
SE9602822D0 (sv) New receptor
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
DE59809344D1 (de) Disubstituierte biphenyloxazoline
ATE310392T1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ITFE930013U1 (it) Bacchette orientali meccanizzate.
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ITPD960101U1 (it) Aceto di miele balsamico
ATE97814T1 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin- profils.
ATE74503T1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee